Goldman Sachs Downgrades Impax Laboratories To Neutral

Analysts at Goldman Sachs downgraded

from Buy to Neutral. The price target for Impax Laboratories has been raised from $33.00 to $41.00. Impax Laboratories shares have climbed 77.61% over the past 52 weeks, while the S&P 500 index has surged 13.71% in the same period. Impax Laboratories' shares declined 0.33% to close at $39.11 yesterday.